Use of GPIIb/IIIa inhibitors in cardiovascular medicine (Q40523922)

21 September 2017

1 reference

title

Use of GPIIb/IIIa inhibitors in cardiovascular medicine (English)

1 reference

21 September 2017

3

Christoph Bode

1 reference

21 September 2017

Ingo Ahrens

1

1 reference

21 September 2017

Karlheinz Peter

series ordinal

2

1 reference

21 September 2017

publication date

1 July 2003

1 reference

Expert Review of Cardiovascular Therapy

21 September 2017

published in

1 reference

21 September 2017

volume

1

1 reference

21 September 2017

issue

2

1 reference

21 September 2017

page(s)

233-242

1 reference

An Abnormal Platelet Glycoprotein Pattern in Three Cases of Glanzmann's Thrombasthenia

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

Platelet membrane defects in Glanzmann's thrombasthenia. Evidence for decreased amounts of two major glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

Conformational regulation of integrin structure and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

Identification of a region in the integrin beta3 subunit that confers ligand binding specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

The GP IIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18, alphaMbeta2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

Heparin inhibits ligand binding to the leukocyte integrin Mac-1 (CD11b/CD18).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reop

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

ACC/AHA Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction--2002: Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice G

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

Surgical revascularization versus thrombolysis for nonembolic lower extremity native artery occlusions: results of a prospective randomized trial. The STILE Investigators. Surgery versus Thrombolysis for Ischemia of the Lower Extremity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

Tissue plasminogen activator for acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.2.233

21 January 2018

Identifiers

DOI

10.1586/14779072.1.2.233

1 reference

21 September 2017

1 reference